Product Description
Propranolol can be used to ameliorate the sympathetic response in angina, tachyarrhythmias, prevention of acute ischemic attacks, migraine prophylaxis, and restless leg syndrome. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557801/)
Mechanisms of Action: ADRB Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Myocardial Infarction | Hypertension | Stroke | Hemangioma
Known Adverse Events: Dizziness | Constipation | Respiratory Tract Infections | Diarrhea
Company: Pierre Fabre
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, China, Denmark, Norway, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Stress Disorders, Post-Traumatic
Phase 2: Melanoma|Multiple Myeloma|Postural Orthostatic Tachycardia Syndrome|Sarcoma
Phase 1: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROPANE | P2 |
Active, not recruiting |
Sarcoma |
2029-02-15 |
|
| ULB-PTSD-Propranolol | P2 |
Unknown Status |
Stress Disorders, Post-Traumatic |
2029-02-01 |
|
| SA2115 | P2 |
Unknown Status |
Sarcoma |
2028-12-31 |
|
| REB19-1437 | P2 |
Recruiting |
Postural Orthostatic Tachycardia Syndrome |
2025-12-31 |